<DOC>
	<DOCNO>NCT01585558</DOCNO>
	<brief_summary>The primary objective study ass long-term safety 30- 60-mg daily dos ospemifene treatment Vulvar Vaginal Atrophy ( VVA ) postmenopausal woman intact uterus .</brief_summary>
	<brief_title>Long-Term Safety 30 mg 60 mg Oral Daily Dose Ospemifene Treatment Vulvar Vaginal Atrophy ( VVA ) Postmenopausal Women With Intact Uterus</brief_title>
	<detailed_description />
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Vaginal Diseases</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Postmenopausal woman age 40 80 year diagnosis vulvar vaginal atrophy ( VVA ) assess vaginal pH , maturation index vaginal smear , selfreported symptom Baseline Protocol 1550310 Had intact uterus Met inclusion exclusion criterion Protocol 1550310 Had complete Protocol 1550310 Had clinically significant abnormal finding Week 12 End Study visit Protocol 1550310 Had physical mental condition , opinion investigator , may interfere subject 's ability comply study procedure</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Menopausal symptom</keyword>
	<keyword>Urogenital atrophy</keyword>
	<keyword>Vulvar vaginal atrophy menopausal woman</keyword>
	<keyword>Vaginal atrophy</keyword>
</DOC>